◈ Nootpedia
Compact view
Research pass: medium Compound SKIP-PERMANENT HIGH

Novolin R (regular human insulin)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Off-label bodybuilding use carries acute lethal hypoglycemia risk for any non-diabetic. Dylan is 20, lean, insulin-sensitive, untested AAS-naive — there is no scenario where exogenous insulin makes sense. Would change only if Dylan develops type 1 diabetes (medically necessary) — which is unrelated to biohacker use.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT

    Lethal-overdose risk dwarfs any speculative benefit. Brain priority + hypoglycemia risk = automatic skip (severe hypoglycemia causes neuronal death).

  • 30-50, executive maintenance
    SKIP-PERMANENT

    for non-diabetic. If diabetic, follow endocrinologist.

  • 50+, mild cognitive decline
    SKIP-PERMANENT

    Hypoglycemia accelerates cognitive decline.

  • Anxiety-prone
    SKIP-PERMANENT

    Hypoglycemia symptoms mimic panic — unbearable.

  • High athletic load, tested status
    SKIP-PERMANENT

    WADA-prohibited (S2.4) — yes, even for non-diabetics.

  • Sleep-disordered
    SKIP-PERMANENT

    Nocturnal hypoglycemia is a known killer.

  • Recovery-focused
    SKIP-PERMANENT
  • Strength/anabolic-focused (35+, experienced AAS user, full medical supervision, accepts mortality risk)
    T

    is the only profile with any tradition of use, and even within IFBB-pro circles the deaths are well-known. Verdict still SKIP for any biohacker not already deeply embedded in supervised pro-bodybuilding context. Outside of that — SKIP-PERMANENT.

  • Diabetic (T1DM, T2DM with insulin requirement)
    PRIMARY TREATMENT

    entirely different decision frame, follow endocrinology.

▸ Subjective experience (deep)

Within 30-60 min of injection without adequate carb intake: hunger, sweating, tremor, palpitations, anxiety, confusion → progressing to seizure, coma, death. With adequate carbs: warm flush, mild fatigue, hunger, "muscle pump" feeling some users report. No euphoric or cognitive effect.

▸ Tolerance + cycling deep dive
  • Insulin sensitivity declines with chronic use of exogenous insulin in non-diabetics; can blunt endogenous response.
  • No protective cycling — each dose carries the same hypoglycemia risk.
▸ Stacking deep dive

Synergistic with

  • In bodybuilding context (DO NOT REPLICATE): Often stacked with HGH, IGF-1, AAS for "GH-insulin-AAS triad." Compounds risk dramatically.

Avoid stacking with

  • Beta blockers (mask hypoglycemia symptoms — life-threatening combo)
  • Alcohol (impairs gluconeogenesis, prolongs hypoglycemia)
  • Other glucose-lowering agents

Neutral / safe co-administration

N/A — entire compound is unsafe in non-diabetic biohacker context.

▸ Drug interactions deep dive
  • Glucocorticoids antagonize (raise glucose)
  • Beta blockers mask warning signs of hypoglycemia (CRITICAL)
  • Salicylates, ACE inhibitors potentiate hypoglycemia
  • Sulfonylureas, GLP-1 agonists additive
▸ Pharmacogenomics
  • INSR mutations (severe insulin resistance syndromes) — not relevant in biohacker population
  • TCF7L2 variants modify diabetes risk but don't change exogenous insulin pharmacology
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC (US) Walmart ReliOn / pharmacy ~$25/vial 100 IU/mL × 10 mL high Available without prescription in US — legality ≠ wisdom
Pharmacy Rx various similar high Often required outside US

For Dylan: Don't source. The cheap, easy access is part of why this kills people — no friction to acquisition.

▸ Biomarkers to track (deep)
  • Baseline (if ever considering — DON'T): HbA1c, fasting glucose, fasting insulin, c-peptide, HOMA-IR
  • During use (medical only): Capillary glucose 4-7×/day, HbA1c quarterly
  • Post-cycle: N/A — not a cycling compound
▸ Controversies / open debates Live debate
  • Does exogenous insulin add anything to a healthy lifter's hypertrophy beyond eating carbs? Mechanistically suspect — endogenous insulin already pulses high after a high-carb meal. Most peer-reviewed work suggests no meaningful added effect on protein synthesis above what amino acid intake already triggers via mTOR.
  • OTC availability vs lethality. US allows OTC purchase of regular human insulin. This was a public-health win for diabetics who couldn't afford analogs but creates a low-friction path for misuse. Several bodybuilder coroner reports specifically cite the OTC accessibility.
  • Intranasal insulin is a different file (intranasal-insulin.md) — that's a memory/cognition application without systemic glycemic effect because BBB delivery bypasses peripheral receptors. Don't conflate.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-PERMANENT HIGH. Documented to close the loop on AAS-stacking insulin question and ensure no future "should Dylan try slin?" recommendation accidentally surfaces. The answer is no, forever, for this profile.
▸ Open questions / gaps Open
  • Whether any future fast-acting insulin formulation engineered for hypoglycemia-resistance (glucose-responsive) might change the calculus — currently theoretical.
  • Long-term cancer signal of supraphysiologic insulin exposure in non-diabetic users — epidemiologic data essentially nonexistent due to off-label use being underground.
▸ Sources (full, with our context)
Back to compact view